Orexo acquires right to digital treatment of opioid dependence

Swedish drug group Orexo has signed a deal that grants the company the rights to a digital treatment of opioid addiction from Gaia. CEO Nikolaj Sørensen aims for commercialization in the US in 2022.

Photo: PR/ Orexo

Log in to read our articles

Welcome to MedWatch. A part of our content is exclusive and reserved for our users.

Try us for 14 days

Try a trial subscription for access to our quality journalism

Related articles